Sethu Sankaranarayanan
United Nations Economic and Social Commission for Asia and the Pacific · Escape Therapeutics (United States)
In this database
2
2023
DB Citations
10
across indexed articles
h-index
28
OpenAlex (all works)
Total Citations
2,656
OpenAlex (all works)
2 articles in Glaucoma Journal Club
Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates.
Following IVT administration, ANX007 distributes to sites within the retina that are relevant to neurodegenerative ophthalmic disease with clear evidence of C1q target engagement.
Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma.
ANX007 intravitreal injections for glaucoma were well-tolerated and effectively engaged the C1q target, suggesting potential for monthly dosing. This supports further investigation in neurodegenerative eye diseases.